The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Neuroprotective effects of goshajinkigan (TJ-107) in colorectal cancer patients receiving oxaliplatin-based chemotherapy: A double-blind, placebo-controlled, randomized phase II trial from the GONE Study Group.
T. Matsui
No relevant relationships to disclose
T. Kono
No relevant relationships to disclose
T. Hata
No relevant relationships to disclose
Y. Munemoto
No relevant relationships to disclose
M. Fukunaga
No relevant relationships to disclose
N. Nagata
No relevant relationships to disclose
M. Nishioka
No relevant relationships to disclose
J. Hasegawa
No relevant relationships to disclose
K. Kunieda
No relevant relationships to disclose
S. Morita
No relevant relationships to disclose
J. Sakamoto
No relevant relationships to disclose
H. Mishima
No relevant relationships to disclose